[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor

Exclusion Criteria

• •Patients with atypical non-idiopathic Parkinson's syndrome (multi system atrophy, progressive supranuclear palsy, etc.)
• •Patients treated with deep brain stimulation
• •Patients with functional psychogenic movements
• •Patients with severe and progressive psychiatric disorders
• •Patients with disabling dyskinesia or essential tremor that are incompatible with imaging studies
• •Patients who have had an ionizing radiation examination on the brain within the last 3 months
• •Individuals with a contraindication to PET or SPECT imaging:
• •* Patients with claustrophobia
• •* Patients refusing to be informed in case of abnormalities detected during imaging tests
• •* Patients treated with amphetamines, benzatropine, amfebutamone, cocaine, mazindol, methylphenidate, phentermine or sertraline
• •* Individuals with a known allergy to the active substance or one of the excipients of the product under investigation or to the reference product or to or to thyroid treatment
• •Woman of childbearing age without effective contraception in the opinion of the investigator
• •Any other serious unstabilized chronic condition deemed incompatible with the study by the investigator
• •Patients unable to sign the informed consent
• •Patients participating in a protocol or in a period of exclusion from a protocol
• •Patients who received compensation of more than 6000 € in the last 12 months prior to enrollment in clinical studies
• •Patients in a period of exclusion from the national volunteer database during which they cannot participate in another clinical study
• •Patients not affiliated with a social security scheme
• •Patients refusing to participate
• •Individuals referred to in articles L. 1121-5 to L. 1121-8 and L1122-2 of the French Public Health Code